Brought to you by 
Teva and Checkpoint Therapeutics agree to collaborate on CEP8983/CEP9722 for cancer
07 Jan 2016
Executive Summary
Checkpoint Therapeutics Inc. licensed exclusive worldwide rights to develop and commercialize CEP8983 (along with its small molecule prodrug, CEP9722) from Teva Pharmaceutical Industries Ltd.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Teva and Checkpoint Therapeutics agree to collaborate on CEP8983/CEP9722 for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice